Cargando…
HIV genotypic resistance among pregnant women initiating ART in Uganda: a baseline evaluation of participants in the Option B+ clinical trial
BACKGROUND: Pre-treatment HIV drug resistance is a threat to elimination of mother to child HIV transmission and could lead to virological failure among HIV-positive pregnant women. We analysed genotypic HIV drug resistance (HIVDR) of baseline samples of participants enrolled in the Option B+ clinic...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Makerere Medical School
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117495/ https://www.ncbi.nlm.nih.gov/pubmed/37092059 http://dx.doi.org/10.4314/ahs.v22i4.48 |
_version_ | 1785028623592325120 |
---|---|
author | Amone, Alexander Wavamunno, Priscilla Gabagaya, Grace Rukundo, Gordon Namale-Matovu, Joyce Malamba, Samuel S Lubega, Irene Homsy, Jaco King, Rachel Nakabiito, Clemensia Nolan, Monica Fowler, Mary Glenn Musoke, Philippa |
author_facet | Amone, Alexander Wavamunno, Priscilla Gabagaya, Grace Rukundo, Gordon Namale-Matovu, Joyce Malamba, Samuel S Lubega, Irene Homsy, Jaco King, Rachel Nakabiito, Clemensia Nolan, Monica Fowler, Mary Glenn Musoke, Philippa |
author_sort | Amone, Alexander |
collection | PubMed |
description | BACKGROUND: Pre-treatment HIV drug resistance is a threat to elimination of mother to child HIV transmission and could lead to virological failure among HIV-positive pregnant women. We analysed genotypic HIV drug resistance (HIVDR) of baseline samples of participants enrolled in the Option B+ clinical trial in Uganda. METHODS: HIV-infected pregnant women attending antenatal care were enrolled from Uganda's National Referral Hospital (Mulago) and Mityana District general hospital and surrounding health centers (HCs). Genotypic HIV testing was performed on blood samples from the first 135 enrolled women out of a subset of 136 participants (25%) who had a baseline VL>1000 copies/mL as one sample failed to amplify. RESULTS: 159/540 (29.4%) had a VL < 1000 copies/ml and 381/540 (70.6%) had a VL >1,000 copies/ml. Of the women with VL>1000 copies/ml, 32 (23.7%) had resistance mutations including 29/135 (21.5%) NNRTI mutations, 6/135 (4.4%) NRTI mutations and 3/135 (2.2%) had both NNRTI and NRTI mutations. The most common NNRTI resistance mutations were: K103KN (5), K103N (5), V179T (4) and E138A (4). CONCLUSIONS: One quarter of the HIV-infected pregnant women in this trial at baseline had NNRTI genotypic resistance mutations. Our findings support new WHO guidelines for first-line ART that were changed to dolutegravir-based regimens. |
format | Online Article Text |
id | pubmed-10117495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Makerere Medical School |
record_format | MEDLINE/PubMed |
spelling | pubmed-101174952023-04-21 HIV genotypic resistance among pregnant women initiating ART in Uganda: a baseline evaluation of participants in the Option B+ clinical trial Amone, Alexander Wavamunno, Priscilla Gabagaya, Grace Rukundo, Gordon Namale-Matovu, Joyce Malamba, Samuel S Lubega, Irene Homsy, Jaco King, Rachel Nakabiito, Clemensia Nolan, Monica Fowler, Mary Glenn Musoke, Philippa Afr Health Sci Articles BACKGROUND: Pre-treatment HIV drug resistance is a threat to elimination of mother to child HIV transmission and could lead to virological failure among HIV-positive pregnant women. We analysed genotypic HIV drug resistance (HIVDR) of baseline samples of participants enrolled in the Option B+ clinical trial in Uganda. METHODS: HIV-infected pregnant women attending antenatal care were enrolled from Uganda's National Referral Hospital (Mulago) and Mityana District general hospital and surrounding health centers (HCs). Genotypic HIV testing was performed on blood samples from the first 135 enrolled women out of a subset of 136 participants (25%) who had a baseline VL>1000 copies/mL as one sample failed to amplify. RESULTS: 159/540 (29.4%) had a VL < 1000 copies/ml and 381/540 (70.6%) had a VL >1,000 copies/ml. Of the women with VL>1000 copies/ml, 32 (23.7%) had resistance mutations including 29/135 (21.5%) NNRTI mutations, 6/135 (4.4%) NRTI mutations and 3/135 (2.2%) had both NNRTI and NRTI mutations. The most common NNRTI resistance mutations were: K103KN (5), K103N (5), V179T (4) and E138A (4). CONCLUSIONS: One quarter of the HIV-infected pregnant women in this trial at baseline had NNRTI genotypic resistance mutations. Our findings support new WHO guidelines for first-line ART that were changed to dolutegravir-based regimens. Makerere Medical School 2022-12 /pmc/articles/PMC10117495/ /pubmed/37092059 http://dx.doi.org/10.4314/ahs.v22i4.48 Text en © 2022 Amone A et al. https://creativecommons.org/licenses/by/4.0/Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Amone, Alexander Wavamunno, Priscilla Gabagaya, Grace Rukundo, Gordon Namale-Matovu, Joyce Malamba, Samuel S Lubega, Irene Homsy, Jaco King, Rachel Nakabiito, Clemensia Nolan, Monica Fowler, Mary Glenn Musoke, Philippa HIV genotypic resistance among pregnant women initiating ART in Uganda: a baseline evaluation of participants in the Option B+ clinical trial |
title | HIV genotypic resistance among pregnant women initiating ART in Uganda: a baseline evaluation of participants in the Option B+ clinical trial |
title_full | HIV genotypic resistance among pregnant women initiating ART in Uganda: a baseline evaluation of participants in the Option B+ clinical trial |
title_fullStr | HIV genotypic resistance among pregnant women initiating ART in Uganda: a baseline evaluation of participants in the Option B+ clinical trial |
title_full_unstemmed | HIV genotypic resistance among pregnant women initiating ART in Uganda: a baseline evaluation of participants in the Option B+ clinical trial |
title_short | HIV genotypic resistance among pregnant women initiating ART in Uganda: a baseline evaluation of participants in the Option B+ clinical trial |
title_sort | hiv genotypic resistance among pregnant women initiating art in uganda: a baseline evaluation of participants in the option b+ clinical trial |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117495/ https://www.ncbi.nlm.nih.gov/pubmed/37092059 http://dx.doi.org/10.4314/ahs.v22i4.48 |
work_keys_str_mv | AT amonealexander hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT wavamunnopriscilla hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT gabagayagrace hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT rukundogordon hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT namalematovujoyce hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT malambasamuels hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT lubegairene hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT homsyjaco hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT kingrachel hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT nakabiitoclemensia hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT nolanmonica hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT fowlermaryglenn hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial AT musokephilippa hivgenotypicresistanceamongpregnantwomeninitiatingartinugandaabaselineevaluationofparticipantsintheoptionbclinicaltrial |